openPR Logo
Press release

Smoking Cessation and Nicotine Addiction Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Pfizer, Inc., Cipla Ltd., Novartis, GlaxoSmithKline plc, Takeda Pharma, McNeil AB

07-18-2024 08:42 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Smoking Cessation and Nicotine Addiction Market Forecasted

DelveInsight's "Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Smoking Cessation and Nicotine Addiction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Smoking Cessation and Nicotine Addiction Market Forecast
https://www.delveinsight.com/sample-request/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Smoking Cessation and Nicotine Addiction Market Report:
• The Smoking Cessation and Nicotine Addiction market size was valued approximately USD 2,311 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, there were 46,814,225 prevalent cases of smoking cessation in the 7MM, with 23,145,916 of those cases occurring in the US. During the predicted timeframe (2023-2032), these cases should decline
• In the United States, tobacco usage was widely frequent in 31,414,398 males and 20,084,615 females in 2022, though this number is expected to decline over the course of the forecast period
• In the US, the age groups with the highest rates of tobacco use in 2022 were 25-44 years of age with 22,659,566 cases, followed by 45-64 years with 18,539,645 cases, 65 and over with 5,664,891 cases, and 18-24 years with 4,634,911 cases
• In Japan, there were 20,842,435 prevalent cases of tobacco usage as of 2022. During the projected period (2023-2032), these cases are anticipated to decline at a considerable CAGR
• The prevalence of nicotine dependence cases among cigarette smokers in the EU4 and the UK was 35,049,259 in 2022; these instances are anticipated to decline over the course of the study
• During the Smoking Cessation and Nicotine Addiction forecast period (2023-2032), AXS-05, Cytisinicline (Cytisine), and NFL-101 are anticipated to enter the market. Since the 1960s, Cytisine has been used to treat nicotine addiction and smoking cessation in a number of Central and Eastern European nations. It is less expensive than other cessation drugs and has minimal known negative effects.
• Key Smoking Cessation and Nicotine Addiction Companies: Pfizer, Inc., Cipla Ltd., Novartis, GlaxoSmithKline plc, Takeda Pharma, McNeil AB, Revolymer plc, Imperial Tobacco Ltd., VMR Products, LLC., Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Currax Pharmaceuticals, Omeros Corporation, Axsome Therapeutics, McNeil AB, and others., and others
• Key Smoking Cessation and Nicotine Addiction Therapies: Cytisinicline, NFL-101, EMB-001, CX-101, OMS-405, AXS-05, GSK598809, Nicotine Gum, and others
• The Smoking Cessation and Nicotine Addiction epidemiology based on gender analyzed that, in the US the prevalence of tobacco use is higher in males than females
• The Smoking Cessation and Nicotine Addiction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Smoking Cessation and Nicotine Addiction pipeline products will significantly revolutionize the Smoking Cessation and Nicotine Addiction market dynamics.

Smoking Cessation and Nicotine Addiction Overview
When tobacco use is repeated, a group of behavioural, cognitive, and physiological phenomena known as nicotine/tobacco dependence emerge. These phenomena typically include a strong desire to smoke, difficulty in controlling one's use, persistence in smoking despite negative effects, giving smoking a higher priority than other activities and obligations, increased tolerance, and occasionally a physical withdrawal state.

Get a Free sample for the Smoking Cessation and Nicotine Addiction Market Report:
https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Smoking Cessation and Nicotine Addiction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Smoking Cessation and Nicotine Addiction Epidemiology Segmentation:
The Smoking Cessation and Nicotine Addiction market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Smoking Cessation and Nicotine Addiction
• Prevalent Cases of Smoking Cessation and Nicotine Addiction by severity
• Gender-specific Prevalence of Smoking Cessation and Nicotine Addiction
• Diagnosed Cases of Episodic and Chronic Smoking Cessation and Nicotine Addiction

Download the report to understand which factors are driving Smoking Cessation and Nicotine Addiction epidemiology trends @ Smoking Cessation and Nicotine Addiction Epidemiology Forecast
https://www.delveinsight.com/sample-request/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Smoking Cessation and Nicotine Addiction Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Smoking Cessation and Nicotine Addiction market or expected to get launched during the study period. The analysis covers Smoking Cessation and Nicotine Addiction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Smoking Cessation and Nicotine Addiction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Smoking Cessation and Nicotine Addiction Therapies and Key Companies
• Cytisinicline: Achieve Life Sciences
• NFL-101: NFL Biosciences SAS
• EMB-001: Embera NeuroTherapeutics
• CX-101: Currax Pharmaceuticals
• OMS-405: Omeros Corporation
• AXS-05: Axsome Therapeutics

Discover more about therapies set to grab major Smoking Cessation and Nicotine Addiction market share @ Smoking Cessation and Nicotine Addiction Treatment Market
https://www.delveinsight.com/sample-request/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Smoking Cessation and Nicotine Addiction Market Strengths
• Advancements in treatment with emerging drugs that are expected to have novel MoAs and rapid onset of action

Smoking Cessation and Nicotine Addiction Market Opportunities
• Lucrative opportunities are available to address unmet therapeutic needs in the smoking and nicotine deaddiction drug market as the existing pipeline remains insufficient

Scope of the Smoking Cessation and Nicotine Addiction Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Smoking Cessation and Nicotine Addiction Companies: Pfizer, Inc., Cipla Ltd., Novartis, GlaxoSmithKline plc, Takeda Pharma, McNeil AB, Revolymer plc, Imperial Tobacco Ltd., VMR Products, LLC., Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Currax Pharmaceuticals, Omeros Corporation, Axsome Therapeutics, McNeil AB, and others., and others
• Key Smoking Cessation and Nicotine Addiction Therapies: Cytisinicline, NFL-101, EMB-001, CX-101, OMS-405, AXS-05, GSK598809, Nicotine Gum, and others
• Smoking Cessation and Nicotine Addiction Therapeutic Assessment: Smoking Cessation and Nicotine Addiction current marketed and Smoking Cessation and Nicotine Addiction emerging therapies
• Smoking Cessation and Nicotine Addiction Market Dynamics: Smoking Cessation and Nicotine Addiction market drivers and Smoking Cessation and Nicotine Addiction market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Smoking Cessation and Nicotine Addiction Unmet Needs, KOL's views, Analyst's views, Smoking Cessation and Nicotine Addiction Market Access and Reimbursement

To know more about Smoking Cessation and Nicotine Addiction companies working in the treatment market, visit @ Smoking Cessation and Nicotine Addiction Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Smoking Cessation and Nicotine Addiction Market Report Introduction
2. Executive Summary for Smoking Cessation and Nicotine Addiction
3. SWOT analysis of Smoking Cessation and Nicotine Addiction
4. Smoking Cessation and Nicotine Addiction Patient Share (%) Overview at a Glance
5. Smoking Cessation and Nicotine Addiction Market Overview at a Glance
6. Smoking Cessation and Nicotine Addiction Disease Background and Overview
7. Smoking Cessation and Nicotine Addiction Epidemiology and Patient Population
8. Country-Specific Patient Population of Smoking Cessation and Nicotine Addiction
9. Smoking Cessation and Nicotine Addiction Current Treatment and Medical Practices
10. Smoking Cessation and Nicotine Addiction Unmet Needs
11. Smoking Cessation and Nicotine Addiction Emerging Therapies
12. Smoking Cessation and Nicotine Addiction Market Outlook
13. Country-Wise Smoking Cessation and Nicotine Addiction Market Analysis (2019-2032)
14. Smoking Cessation and Nicotine Addiction Market Access and Reimbursement of Therapies
15. Smoking Cessation and Nicotine Addiction Market Drivers
16. Smoking Cessation and Nicotine Addiction Market Barriers
17. Smoking Cessation and Nicotine Addiction Appendix
18. Smoking Cessation and Nicotine Addiction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Smoking Cessation and Nicotine Addiction Pipeline
https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-deaddiction-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Smoking Cessation and Nicotine Addiction Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Smoking Cessation and Nicotine Addiction market. A detailed picture of the Smoking Cessation and Nicotine Addiction pipeline landscape is provided, which includes the disease overview and Smoking Cessation and Nicotine Addiction treatment guidelines.

Smoking Cessation and Nicotine Addiction Epidemiology
https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Smoking Cessation and Nicotine Addiction Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Smoking Cessation and Nicotine Addiction epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
DelveInsight's "Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Idiopathic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Inguinal Hernia Market
https://www.delveinsight.com/report-store/inguinal-hernia-market
DelveInsight's "Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Inguinal Hernia, historical and forecasted epidemiology as well as the Inguinal Hernia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Charcot-marie-tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Smoking Cessation and Nicotine Addiction Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Pfizer, Inc., Cipla Ltd., Novartis, GlaxoSmithKline plc, Takeda Pharma, McNeil AB here

News-ID: 3589076 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Nicotine

Nicotine Pouch Market Expansion Driven by Rising Demand for Smokeless, Discreet, …
Nicotine Pouch Market size was valued at USD 3.76 Billion in 2024 and the total Nicotine Pouch revenue is expected to grow at a CAGR of 35.8% from 2025 to 2032, reaching nearly USD 43.50 Billion. Nicotine Pouch Market Overview: The Nicotine Pouch Market is experiencing robust growth as consumers increasingly seek alternatives to traditional tobacco products. Nicotine pouches are smokeless, spit-free products that provide controlled nicotine delivery without combustion, making them
Oral Nicotine Products Market Is Booming So Rapidly | Major Giants Nicotine Pouc …
HTF MI recently introduced Global Oral Nicotine Products Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2025-2033). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence. Major companies in Oral Nicotine Products Market are: Swedish Match (Sweden), Altria (USA), British American Tobacco (UK), Philip Morris International (USA/Switzerland),
Nicotine and Nicotine Salts Market | Exploring Current Trends and Growth Status …
Nicotine and Nicotine Salts Market Outlook and Investment Analysis What is the current outlook of the Nicotine and Nicotine Salts market? The Nicotine and Nicotine Salts market is experiencing rapid growth driven by rising consumer demand for e-cigarettes and other nicotine delivery systems. Increasing awareness about smoking cessation products, along with the shift towards less harmful alternatives like vaping, has contributed to the market's expansion. The rising trend of e-cigarette usage, particularly
Sofi Surge Zero Nicotine: A Revolutionary Leap in Nicotine-Free Vaping
[Tustin, 09.12.2024] - The vaping industry is transformed once again with the introduction of the Sofi Surge Zero Nicotine, a cutting-edge disposable device designed for those seeking a nicotine-free vaping experience. This innovative product is poised to make waves among vapers who desire the pleasure of vaping without the addictive component of nicotine, while still enjoying unmatched flavor and convenience. With a remarkable 25,000 puff capacity, the Sofi Surge Zero Nicotine
Global Nicotine Market Research Report
This report studies the global Nicotine market status and forecast, categorizes the global Nicotine market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Alchem International Siegfried CAMBREX CHARLES CITY FERTIN PHARMA JOHNSON AND JOHNSON CONSUMER INC Laboratorios Haymann Mallinckrodt Pharmaceuticals PORTON FINE
Global Nicotine Polacrilex Market Research Report
This report studies the global Nicotine Polacrilex market status and forecast, categorizes the global Nicotine Polacrilex market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report BGP HEALTHCARE Cambrex Corporate Nicobrand Alchem International DIXIE CHEMICAL FERTIN PHARMA Laboratorios Haymann MALLINCKRODT NICOBRAND PORTON FINE